Roxindole: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Roxindole.png|Roxindole | |||
</gallery> | |||
Latest revision as of 01:19, 20 February 2025
Roxindole is a dopamine agonist that was originally developed in the 1980s. It is a derivative of indole, and has been studied for its potential use in the treatment of Parkinson's disease and schizophrenia.
History[edit]
Roxindole was first synthesized in the 1980s by the pharmaceutical company Sandoz. It was initially developed as a potential treatment for Parkinson's disease, due to its ability to stimulate dopamine receptors in the brain.
Pharmacology[edit]
Roxindole acts as a dopamine agonist, meaning it stimulates the activity of dopamine receptors in the brain. It has a high affinity for the D2 and D3 dopamine receptors, and a lower affinity for the D1 receptor.
In addition to its dopamine agonist activity, roxindole also has some affinity for the serotonin 5-HT1A and 5-HT2A receptors, and the adrenergic alpha-1 and alpha-2 receptors.
Clinical Use[edit]
While roxindole was initially developed for the treatment of Parkinson's disease, it has also been studied for its potential use in the treatment of schizophrenia. However, as of 2021, it is not currently approved for use in any country.
Side Effects[edit]
As with any medication, roxindole has the potential to cause side effects. These can include nausea, vomiting, dizziness, and insomnia. In rare cases, it can also cause more serious side effects such as hallucinations and psychosis.
